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Therapeutics that target ERBB2, such as lapatinib,
often provide initial clinical benefit, but resistance
frequently develops. Adaptive responses leading
to lapatinib resistance involve reprogramming of
the kinome through reactivation of ERBB2/ERBB3
signaling and transcriptional upregulation and acti-
vation of multiple tyrosine kinases. The heterogene-
ity of induced kinases prevents their targeting by a
single kinase inhibitor, underscoring the challenge
of predicting effective kinase inhibitor combination
therapies. We hypothesized that, to make the tumor
response to single kinase inhibitors durable, the
adaptive kinome response itself must be inhibited.
Genetic and chemical inhibition of BET bromodo-
main chromatin readers suppresses transcription
of many lapatinib-induced kinases involved in resis-
tance, including ERBB3, IGF1R, DDR1, MET, and
FGFRs, preventing downstream SRC/FAK signaling
and AKT reactivation. Combining inhibitors of ki-
nases and chromatin readers prevents kinome adap-
tation by blocking transcription, generating a durable
response to lapatinib, and overcoming the dilemma
of heterogeneity in the adaptive response.INTRODUCTION
The human epidermal growth factor receptor 2 (HER2/ERBB2) is
a member of the EGFR/ERBB family of receptor tyrosine kinases
(RTKs). The ERBB2 oncogene is amplified or overexpressed in
roughly 25% of breast cancers and serves as the primary driver
of tumor cell growth in the majority of these cancers. Clinical390 Cell Reports 11, 390–404, April 21, 2015 ª2015 The Authorstrials indicate that ERBB2 ‘‘addiction’’ is fundamental to the
behavior of these tumors, and targeting ERBB2 has proved
to be an effective treatment in a subset of ERBB2+ breast
cancer patients. Approved ERBB2-targeting therapies include
the monoclonal antibodies trastuzumab, pertuzumab, and tras-
tuzumab-DM1, an antibody drug conjugate, in addition to the
ATP-competitive EGFR/ERBB2 inhibitor lapatinib. However,
even with initial dramatic clinical responses to these therapies
as single agents or in combination, patients frequently relapse
as resistance develops. The preferred dimerization partner of
ERBB2 is ERBB3/HER3, and a major mechanism of lapatinib
resistance is due to transcriptional and post-translational upre-
gulation of ERBB3 (Amin et al., 2010; Garrett et al., 2011). Multi-
ple other kinases contribute to the resistant phenotype as well,
including IGF1R, MET, FGFR2, FAK, and SRC family kinases
(Azuma et al., 2011; Huang et al., 2011; Rexer and Arteaga,
2012).
Characteristically, tumors have a remarkable resiliency toward
kinase-directed therapeutics, capable of rewiring their signaling
networks to evade effects of the drug and develop resistance.
Targeting specific signaling nodes crucial for tumor growth,
such as PI3K, AKT, mTOR, BRAF, and MEK, elicits adaptive
kinome responses that upregulate alternative kinase signaling
networks or reactivate the targeted pathway to overcome inhib-
itor treatment (Chandarlapaty et al., 2011; Duncan et al., 2012;
Rodrik-Outmezguine et al., 2011; Serra et al., 2011; Sun et al.,
2014). This ‘‘adaptive kinome reprogramming’’ is mechanisti-
cally based on the disruption of feedback and feedforward reg-
ulatory loops that serve to bypass the inhibition and rapidly
generate resistance to targeted therapies. Adaptive bypass re-
sponses in tumor cells are a major reason that kinase inhibitors
often do not have durable responses in the treatment of cancer
patients.
To understand these bypass mechanisms toward ERBB2 inhi-
bition, we investigated lapatinib-induced kinome adaptation in a
panel of ERBB2+ cell lines using a chemical proteomics method.
We find the adaptive kinome response to lapatinib involves the
activation of multiple RTKs, SRC family kinases, FAK, and mem-
bers of other intracellular networks downstream of RTKs. We
additionally identify significant heterogeneity in this response
among different ERBB2+ cell lines. Multiple kinases contribute
to escape from lapatinib-mediated growth inhibition, consistent
with a shift in dependency to alternative signaling nodes in addi-
tion to ERBB2. This prevents their targeting by a single kinase in-
hibitor, underscoring the difficulty of choosing the most effective
kinase inhibitor combinations to treat ERBB2+ tumors. These re-
sults suggest that chasing combination therapies with multiple
kinase inhibitors has a poor likelihood of success. We ap-
proached this problem with the hypothesis that lapatinib would
be more durable in inhibiting ERBB2+ cell growth if we could
block the adaptive reprogramming response itself. We target
chromatin readers involved in transcriptional upregulation of
RTKs that drive the adaptive signaling networks responsible for
lapatinib resistance. By inhibiting the onset of the adaptive
response, we achieve durable growth inhibition greater than
that observed by targeting several different kinases with inhibi-
tors. Our studies demonstrate that inhibiting the adaptive kinome
response provides a method to address the heterogeneity in
kinome adaptation and a mechanism to prevent resistance to
kinase inhibitors.
RESULTS
Lapatinib InducesDynamicAdaptiveKinomeResponses
in ERBB2+ Breast Cancer Cells
We used multiplexed inhibitor beads coupled with mass spec-
trometry (MIB/MS) to quantitatively measure dynamic changes
in kinase activity on a proteomic scale (Figure 1A) (Duncan
et al., 2012). SKBR-3 and BT474 luminal ERBB2+ breast cancer
cells were treated with lapatinib for 4, 24, and 48 hr (Figures 1B,
S1A, and S1B). The kinome of SKBR-3 cells is remarkably
responsive to lapatinib with many kinases displaying enhanced
MIB binding, indicative of increased kinase activity relative to un-
treated cells. Lapatinib induces growth inhibition, and there is a
concomitant time-dependent loss of MIB binding of cell-cycle-
regulating kinases, correlating with inhibition of their kinase ac-
tivity. Loss of ERBB2 and EGFR MIB binding was observed in
both SKBR-3 and BT474 cells at 4 hr, but in SKBR-3 cells,
ERBB2 binding had returned to untreated levels after 48 hr, indi-
cating reactivation of ERBB2 (Figures 1B and 1C). In BT474 cells,
ERBB2 remains inhibited at 48 hr. ERBB3 binding to MIBs in-
creases within 24 hr, consistent with ERBB3 upregulation in
response to lapatinib (Amin et al., 2010). The time course illus-
trates the dynamic behavior of the kinome with kinases having
temporal differences in regulation of their activity (Figures 1D,
1E, and S1A). EGFR displays rapid and sustained loss of MIB
binding, while most inhibited kinases demonstrate a progressive
loss of MIB binding over 48 hr of lapatinib treatment. Some ki-
nases display similar reactivation dynamics to ERBB2 (IGF1R,
PTK6, ADCK1), suggesting they operate in a common regulatory
network. Others such as ERBB3, AKT1, DDR1, and ARAF are
initially inhibited but reactivate with greater MIB binding than
their baseline control activity. Kinases such as FGFR2 respond
with increased activity within 4 hr, while other tyrosine kinases(TKs) such as FRK, YES, FAK1, and JAK1 become progressively
more activated, suggesting they are regulated downstream of
the kinases driving the initial adaptive kinome response.Western
blots confirmed MIB/MS results, with inhibition of ERBB family
phosphorylation and downstream signaling (AKT, ERK1/2) at
4 hr and reactivation by 48 hr (Figure 1F). Total protein levels of
EGFR, ERBB2, ERBB3, DDR1, FRK, and PKCd increase over
time, along with activation loop phosphorylation of FAK and
SRC family kinases (SFKs). STAT3 activating phosphorylation
was induced by lapatinib, downstream of JAK signaling and
independent of SFK signaling (Figure S1C). Addition of a higher
dose of lapatinib (1 mM) after 48 hr inhibited partial reactivation
of EGFR, ERBB2, and ERBB3 phosphorylation, but effects on
downstream FAK/SFK/AKT/ERK signaling were limited.
BT474 cells generated a less-robust adaptive response with
more kinases inhibited than activated (Figures 1G and S1B).
BT474 cells displayed a progressive loss of MEK/ERK MIB
binding, but a rebound in AKT signaling similar to SKBR-3
cells, with initial inhibition of AKT1 and overall increase in
AKT2 MIB binding (Figures 1B and 1G). Interestingly, MEK/
ERK MIB binding in SKBR-3 cells was seemingly unchanged
by short-term treatment with lapatinib in the 4-hr MIB/MS pro-
file, suggesting additional inputs regulate their activity. Western
blots of BT474 cells treated with lapatinib demonstrated little re-
activation of ERBB2 and ERBB3, with progressively increasing
IGF1R and INSR phosphorylation and total levels, SFK phos-
phorylation, and a partial return of AKT and ERK1/2 activity
(Figure 1H).
MIB/MS Defines Heterogeneity in the Adaptive Kinome
Response to Lapatinib
Across four independent MIB/MS runs for SKBR-3 cells, we
defined a signature of kinases with highly statistically significant
changes in MIB binding after 48-hr lapatinib treatment (Fig-
ure 2A). Kinases with enhanced MIB binding (increased activity)
include the RTKs DDR1, EPHB3, and FGFR2, non-receptor
TKs JAK1, FAK1, and SFKs FRK and YES, and multiple kinases
involved in cytoskeletal regulation (MYLK3, NEK9, MARK2,
MRCKB, LIMK2). The CMGC kinases CDK5, -10, and -17 and
AGC kinases KPCD (PKCd) and KS6A5 (RSK5) are also acti-
vated. PRKDC (DNA damage sensor), STK3 (HIPPO pathway/
pro-apoptotic signaling), and AAPK1 (AMP-activated) are
activated by multiple growth-inhibiting treatments and likely
represent a stress-induced kinase response. Kinases with loss
of MIB binding within the signature include multiple cell-cycle-
regulating kinases, RTKs EGFR and EPHA2, and serine/threo-
nine kinases KC1A, RIPK2, M3K2, and KS6A1 (RSK1). For
BT474 cells, the 48-hr MIB/MS signature defines a very different
lapatinib response, with activation of INSR, PRPK (TP53-
regulating kinase), ULK3 (autophagy, Hedgehog pathway),
and KS6A4 (RSK4). Opposite from SKBR-3 cells, DDR1, FRK,
NEK9, and cytoskeleton-regulating kinases (MARK3 and
LIMK1) were inhibited (Figure 2A). Of activated kinases, only
YES, KS6A5, PRKDC, and STK3 are common between
SKBR-3 and BT474 cells.
MIB/MS was performed for three additional ERBB2-amplified
cell lines after 48-hr lapatinib treatment: luminal HCC1419 cells
are highly sensitive to lapatinib-induced growth arrest, whileCell Reports 11, 390–404, April 21, 2015 ª2015 The Authors 391
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basal-like HCC1954 and luminal MDA361 cells are more resis-
tant. HCC1954 and MDA361 harbor activating PIK3CA muta-
tions (H1047R and E545K, respectively) and display resistance
to trastuzumab. The kinome of HCC1954 cells is very responsive
with activation of multiple RTKs, PKC isoforms, and CAMKs. In
contrast, the kinome of MDA361 cells was mostly suppressed
by lapatinib, with INSR and IGF1R the only RTKswith statistically
significant increases in MIB binding (Figure 2A). HCC1419 cells
are intermediate in their adaptive response, with four TKs signif-
icantly activated: DDR1, INSR, FAK1, and FRK. Across cell lines,
multiple induced kinases are known to modulate or act down-
stream of ERBB signaling, including SFKs, FAK1, JAK1, CSK,
CDK5, and PKCd, emphasizing an addiction to ERBB-driven
signaling networks (Allen-Petersen et al., 2014; Li et al., 2003).
It was unexpected that the lapatinib adaptive response would
demonstrate such heterogeneity across multiple kinase subfam-
ilies in five ERBB2+ cell lines (Figure 2B, TKs; Figure S2A, other
subfamilies). The responsiveness of the kinome does not seem
to correlate with EGFR/ERBB2 expression or activation level or
the dependency on different ERBB familymembers asmeasured
by RNAi analysis (Figures S2B and S2C).
The RTK family displays significant variability in activity and
response across the five cell lines, but IGF1R/INSR is commonly
activated and EPHA2 is commonly inhibited in all lines (Fig-
ure 2B). Among non-receptor TKs, multiple cell lines activate
FRK, FAK1, and TYK2. SKBR-3 and HCC1954 share a robust
activation of most TKs captured by MIBs. 333 self-organizing
map (SOM) clustering identifies common kinase behavior
between several lines, including induction of PRKDC, STK38,
NEK9, FRK, STK3, and DDR1 (Figures S3A and S3B). A cluster
preferentially induced in HCC1954 includes stress response
kinases (MK09, MK11, MK14, STK24), CSK22 (CK2a), KCC2G
(CAMK2G), KPCD2, and TKs ACK1 and PTK6 (Figure S3C).
Commonly inhibited kinases among the five cell lines include
cell-cycle-regulating kinases as well as KS6B1 (p70 S6 kinase)
(Figure S3D). To understand the variation in kinome response be-
tween cell lines, we utilized principal component analysis (PCA)
(Figure 2C). Principal component 1 (PC1) accounts for themajor-
ity of the variation and separates kinases that are commonly sup-
pressed (STK6, PMYT1, CDK1, EPHA2, CDK4) from those that
are primarily induced (PRKDC, INSR, DDR1) among cell lines. Ki-
nases driving variation between cell lines in PC2 and PC3 agree
with differences observed in 48-hrMIB/MSsignatures (Figure 2A)Figure 1. Lapatinib Induces Dynamic Kinome Responses
(A) Flowchart for experimental design.
(B) MIB/MS kinome activation dynamics over 48 hr of 300 nM lapatinib treatment in
activity), and values <1 indicate decreased MIB binding (decreased activity) relat
biological replicates.
(C) MIB-binding dynamics suggest reactivation of ERBB2 in SKBR-3 cells but co
(D) Hierarchical clustering of MIB-binding ratios in SKBR-3 cells identifies cluste
(E) Dynamics of a select set of kinases illustrates multiple behaviors in response to
inhibited; red, activated.
(F)Western blots validateMIB/MS results and identify upregulation of ERBB3, DDR
and STAT3 in response to lapatinib. AKT and ERK1/2 are inhibited at 4 hr but beco
ERBB2 but has little effect on other kinases.
(G) BT474 MIB-binding dynamics of tyrosine kinases and MEK/ERK and AKT/mT
(H) Western blots indicate upregulation of ERBB3, INSR, and IGF1R total levels
Also see Figure S1.and SOM analysis (Figures S3A–S3D) and provide a statistical
measure of the heterogeneity in the kinome response. These ki-
nases include DDR1, FRK, KPCD, KT3K, CDK5, PTK6, PRPK,
and KS6A4.
mRNA sequencing (RNA-seq) indicated 18%–20% of the tran-
scriptome was modulated at least 2-fold after 48-hr lapatinib
treatment in SKBR-3 and BT474 cells (Figure 2D). Gene ontology
terms enriched in commonly upregulated genes involve regula-
tion of glucose homeostasis and transcription, consistent with a
reactivation of AKT signaling networks and reorganization of a
significant portion of the transcriptome (Figure 2E). Kinases
commonly upregulated 2-fold or more between SKBR-3
and BT474 cells include RTKs INSR, ERBB3, and ERBB4, the
cytoskeleton-regulating kinases TBCK, DCLK2, and TTBK2 and
DYRK1B—a modulator of FOXO transcription (Figure 2F).
ERBB2, PTK7, and DDR1 in SKBR-3 and EPHA7, MERTK,
EPHA4, EGFR, IGF1R, and FGFR2 in BT474 are also upregu-
lated, consistent with a transcriptional component of the adaptive
RTK response. In BT474 cells, IRS2 and IGF1 (both 16-fold) are
among the top 20 upregulated genes, indicating an autocrine/
paracrine feedforward loop activating IGF1R signaling.
Significant Heterogeneity Exists among Kinases that
Compensate for ERBB2 in the Presence of Lapatinib
Given the cluster of INSR/IGF1R activation, reports of
IGF1R/ERBB2/ERBB3 complexes in trastuzumab-resistant cells
(Huang et al., 2010), and the enrichment of glucose signaling net-
works from the RNA-seq data, we investigated the role of IGF1R
and INSR in bypassing ERBB2 inhibition. SKBR-3 and BT474
cells were treated with increasing doses of the INSR/IGF1R
inhibitor BMS754807 (BMS754) in the presence or absence of
lapatinib (Figure 3A). The combination of lapatinib + BMS754
causes a dose-dependent increase in AKT phosphorylation in
SKBR-3 but a decrease in BT474 cells. Combinations of lapati-
nib and BMS754 had little effect on HCC1419 and HCC1954
signaling (Figure S3F), but in MDA361 cells BMS754 alone
reduced phosphorylation of ERBB2, ERBB3, FAK, SFKs, and
AKT S473 and in combination with lapatinib further inhibited
AKT (Figure 3B). Crystal violet colony formation assays demon-
strated the combination of lapatinib and BMS754 significantly
inhibited growth of MDA361 cells, but resistant colonies per-
sisted, and no major enhancement of lapatinib-induced growth
inhibition was observed in other cell lines (Figure 3C). Thus,SKBR-3 cells. Ratios greater than 1 indicate increasedMIB binding (increased
ive to control cells treated with DMSO. Data presented are the average of four
ntinued suppression in BT474 cells.
rs of dynamic kinase behavior.
lapatinib. Four points graphically indicate 0, 4, 24, and 48 hr MIB binding. Blue,
1, FRK, and PKCd and increased activation of FAK, SRC family kinases (SFKs),
me reactivated over 72 hr. Treatment with 1 mM lapatinib re-inhibits EGFR and
OR pathways.
and increase in SFK phosphorylation after lapatinib treatment in BT474 cells.
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co-targeting ERBB2 and the common IGF1R/INSR response
does not provide a successful pan combination therapy.
Lapatinib induces activity and transcription of DDR1, SFKs,
and EPH receptors in multiple cell lines (Figures 2A, 2B, and
2F), all of which are targets for dasatinib, and previous reports
link SFKs to escape from ERBB2-targeted therapies (Rexer
et al., 2011; Zhang et al., 2011). Treatment of SKBR-3 and
BT474 cells with dasatinib caused a loss of MIB binding of
multiple RTKs and TKs and prevented lapatinib-induced MIB
binding (Figure 3D). Colony formation assays demonstrated da-
satinib only modestly enhances lapatinib growth inhibition in
BT474 and MDA361 cells (Figure 3C). Western blots indicated
the combination of lapatinib and dasatinib inhibits activation of
SFKs, AKT, and ERK1/2 but actually increases FAK phosphory-
lation (Figure 3E). Lapatinib induced FAKMIB binding in multiple
cell lines (Figure 2A), and the FAK inhibitor PF573228 in combi-
nation with lapatinib synergized in colony formation assays in
SKBR-3 cells (Figure 3C). PF573228 inhibited FAK and SFK
phosphorylation in the presence or absence of lapatinib (Fig-
ure 3F), suggesting both pathways must be inhibited in the pres-
ence of lapatinib to generate stable growth inhibition.While other
cell lines do not demonstrate such strong synergism seen with
SKBR-3 cells, FAK signaling is crucial for the growth of several
cell lines and FAK inhibition enhances lapatinib growth inhibition.
FGFR2 was induced by lapatinib by MIB/MS (SKBR-3, Fig-
ure 2A) and RNA-seq (BT474, Figure 2F), and FGFR2 has been
implicated in compensating for ERBB2 in the presence of lapati-
nib (Azuma et al., 2011), so we tested lapatinib + a pan-FGFR in-
hibitor (BGJ398). Colony formation assays demonstrated FGFR
inhibition enhances lapatinib growth inhibition and SKBR-3 cells
display moderate synergism between lapatinib and BGJ398
(Figure 3C). Most lines are growth-inhibited by BGJ398 in
the absence of lapatinib, suggesting FGFRs cooperate with
ERBB2 for growth of ERBB2+ cells. Combining lapatinib and
BGJ398 inhibited ERBB2/ERBB3 reactivation and further in-
hibited SFK and FAK phosphorylation in SKBR-3 cells but, in
turn, elicited a stronger AKT/ERK response than lapatinib alone
(Figure 3G). MIB/MS analysis of SKBR-3 cells demonstrated
BGJ398 inhibits lapatinib induction of SFKs, FAK1/2, and
multiple other TKs consistent with FGFR participation in lapati-
nib-induced kinome adaptation (Figure 3H). The combination
of lapatinib and BGJ398 still allowed resistant colony formation
in all five cell lines, suggesting alternative growth-promoting
signaling networks are activated even in response to combined
ERBB/FGFR/SFK/FAK inhibition. Overall, these results identifyFigure 2. MIB/MS and RNA Sequencing Define Heterogeneity in the A
(A) Statistically significant MIB-binding changes after 48-hr lapatinib treatment b
ERBB2+ cell lines depicted graphically. Kinome trees reproduced courtesy of Ce
(B) Lapatinib-induced MIB-binding changes of tyrosine kinases illustrate differe
activation.
(C) Principal component analysis identifies kinases that drive the variation in kinom
line (67 kinases) were used.
(D) Lapatinib induces 2-fold changes up or down in 18%–20% of expressed mR
(E) Gene ontology terms enriched in commonly upregulated mRNAs between SK
as most significant processes.
(F) Kinase mRNAs upregulated by lapatinib at least 2-fold by RNA-seq in SKBR
upregulated kinases.
Also see Figures S2 and S3.multiple kinases that contribute to ERBB2+ cell growth and
reveal heterogeneity in the kinases that compensate for lapati-
nib-mediated ERBB2 inhibition.
Lapatinib-Resistant SKBR-3 and BT474 Depend on
Multiple Kinases for Growth
To further define how the kinome bypasses inhibition of ERBB2,
we generated lapatinib-resistant (LapR) SKBR-3 by continuous
treatment with 300 nM lapatinib for 4+ months and LapR
BT474 by progressively increasing doses of lapatinib every 3–
4 weeks to 300 nM. Resistant lines were kept as a pool of all
clones that grew out. LapR SKBR-3 grow at a similar rate to
parental cells, while LapR BT474 grow somewhat slower than
parental (Figures S4A and S4B). LapR cells were less sensitive
to growth inhibition by ERBB2 knockdown but similarly sensitive
to ERBB3 knockdown as compared to parental cells (Figure 4A).
MIB/MS was used to compare LapR cells to lapatinib-sensitive
parental cells (Figure S4C). Longtail plots of activated kinases
show the most-activated kinases in LapR cells overlap with
48 hr MIB/MS signatures and transcriptome responses of the
parental line and other ERBB2+ lines (Figures 2A, 2F, and 4B).
LapR SKBR-3 and BT474 cells share several activated kinases,
including PRKDC, CDK5, TGFR1, ACVR1, CK1/2, and TKs MET,
DDR1, FGFR2, FRK, and FER. Among RTKs, LapR SKBR-3
display strong activation of ERBB3 and modest increases in
DDR1, FGFR2, and MET, while LapR BT474 activate multiple
FGFRs, EPHA7, MERTK, MET, and IGF1R (Figure 4C). Western
blots indicated inhibition of EGFR/ERBB2 phosphorylation in
LapR cells with upregulation of multiple RTKs and reactivation
of AKT/ERK in SKBR-3 cells but reduced activity of AKT/ERK
in BT474 relative to parental cells (Figure 4D). Knockdown of
ERBB RTKs, FGFR2, DDR1, MET, and CDK5 all provided partial
growth inhibition of LapR SKBR-3 cells, while LapR BT474 cells
are growth-inhibited by ERBB3, FGFR2, and CDK5 knockdown
(Figures 4E and S4D–S4F). Thus, prolonged exposure
to lapatinib causes a broad reorganization of the kinome and
shifts dependency away from ERBB2 and toward multiple other
kinases including several RTKs.
BET Family Bromodomain Inhibition Suppresses
Lapatinib-Induced Kinome Reprogramming
By undertaking this comprehensive analysis, we unveiled signif-
icant heterogeneity in lapatinib-induced kinome adaptation in
ERBB2+ cells and demonstrated the resiliency of the kinome to
bypass combinations of lapatinib and a second kinase inhibitor.daptive Response
ased on Benjamini-Hochberg adjusted p values at FDR of 0.05 and SD in five
ll Signaling Technology.
nces between cell lines and identifies common response of INSR and IGF1R
e response. Kinases captured in at least three out of four MIB/MS runs per cell
NA transcripts.
BR-3 and BT474 cells identify glucose regulation and transcriptional regulation
-3 and BT474. Hatched bars indicate RTKs, and red bars indicate common
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This argues multiple sequential combinations of kinase inhibitors
and possibly intermittent therapies might be necessary to pre-
vent resistance, but rationally choosing such a regimen poses
a significant challenge. Multiple kinases contribute to growth,
and since there is no one drug that can inhibit the activity of all
responsive kinases, we hypothesized that targeting the adaptive
response itself would make lapatinib-induced growth arrest
more durable (Figure 5A). RNA-seq analysis indicated 8%–
10% of the expressed transcriptome is upregulated R2-fold
within 48 hr of lapatinib treatment (Figure 2D). Of significance,
kinases involved in resistance were transcriptionally induced
by lapatinib treatment (e.g., ERBB3, DDR1, FGFR2), as were
many kinases in the 48-hr MIB/MS signature of SKBR-3 cells
(Figure S5A). This is consistent with lapatinib inhibiting AKT
and ERK signaling networks causing FOXO activation and c-
Myc degradation, leading to RTK upregulation (Chandarlapaty
et al., 2011; Duncan et al., 2012). Thus, we decided to target
epigenetic factors—proteins that modify or associate with chro-
matin—to prevent the reprogramming response at a transcrip-
tional level. We tested inhibitors of different epigenetic enzymes
and identified JQ1, an inhibitor of BET family bromodomains
(Delmore et al., 2011) as capable of suppressing lapatinib-
induced kinome reprogramming.
ERBB2+ cell lines were sensitive to growth inhibition by JQ1
and I-BET762, a second BET bromodomain inhibitor (Fig-
ure S5B). Treatment of SKBR-3 cells with JQ1 prevented lapati-
nib-induced phosphorylation and expression of ERBB3, a
primary mediator of the adaptive response leading to AKT
reactivation and lapatinib resistance (Figure 5B). JQ1 also
suppressed lapatinib-induced expression of FGFR2, DDR1,
IGF1R, pFAK, pSFK, and pPKCd across multiple cell lines
(Figure 5C). JQ1 alone has little effect on AKT and p70 S6K
phosphorylation but in combination inhibits the activity of both
kinases more than that seen with lapatinib alone. Increased
PARP cleavage was observed with the combination of lapatinib
and JQ1 versus single agents, indicating an increase in
apoptosis (Figure 5C). JQ1 also inhibited lapatinib-mediated
kinase induction in HCC1954 and MDA361 cells, including
growth-promoting kinases FGFR1, FGFR2, and IGF1R (Fig-Figure 3. Cell Lines Exhibit Variability in Kinases that Drive Growth in
(A) Lapatinib combined with increasing doses of BMS754807 (IGF1R/INSR inhib
BT474 relative to lapatinib treatment alone after 24 hr.
(B) BMS754 inhibits ERBB2/3 phosphorylation as a single agent, and when combi
(C) Colony formation assays indicate heterogeneity in the kinases that contribute to
Dasatinib is additive in BT474 and MDA361 but does not significantly enhance gro
and PF228 (FAK inhibitor) or BGJ398 (FGFR inhibitor), but other cell lines show
combination with lapatinib. SKBR-3, BT474, and HCC1419 were treated for 4 wee
SKBR3; 30 nMBT474; 10 nMHCC1419; 300 nMHCC1954 andMDA361. Data pre
lapatinib alone (p < 0.05).
(D) MIB/MS profile of SKBR-3 and BT474 cells after 48-hr treatment with 300 nM
multiple tyrosine kinases, but not FAK1 and FAK2 in SKBR-3 cells.
(E) Western blots after 48 hr demonstrate dasatinib inhibits lapatinib-induced SF
(F) Western blots after 48 hr indicate PF228 inhibits FAK and SFK phosphorylatio
(G) Western blots indicate FGFR inhibition alone slightly reduces AKT and ERK ph
lapatinib indicates FGFRs regulate ERBB signaling and SFK and FAK phosphory
Media were not changed throughout experiment.
(H) MIB/MS analysis of 300 nM lapatinib, 300 nM BGJ398, or the combination a
(I) Matrix of p values comparing growth inhibition of lapatinib alone versus lapatini
not significant (pR 0.05).ure S5C). Treatment of SKBR-3 cells with another BET inhibitor,
I-BET151, similarly blocked lapatinib-induced expression and
phosphorylation of signature kinases (Figure S5D). Quantitative
RT-PCR (qRT-PCR) analysis demonstrated JQ1 suppresses
or prevents lapatinib-induced transcription of many adaptive
response kinases implicated in resistance, including ERBB3,
DDR1, FGFR2, IGF1R, and MET, in addition to ERBB2 itself (Fig-
ures 5D and S5E).
JQ1 alone only reduced the growth of SKBR-3 andBT474 cells
and resulted in the formation of resistant colonies in 4-week
clonogenic assays but when combined with lapatinib strongly
arrested growth or resulted in regression of cell number and
essentially eliminated colony formation (Figures 5E and 5F).
I-BET762 and I-BET151 elicit similar growth-inhibitory re-
sponses from SKBR-3 and BT474 cells (Figures S6A–S6C). Clo-
nogenic assayswith HCC1419 cells demonstrated combinations
of lapatinib, and BET bromodomain inhibitors suppressed
ERBB2+ cell growthmore effectively than kinase inhibitor combi-
nations with lapatinib (dasatinib, BMS754, PF228, and BGJ398)
(Figure 5G). Growth of HCC1954 and MDA361 cells, which are
more resistant to lapatinib than SKBR-3 or BT474 cells, was
also inhibited by lapatinib + BET bromodomain inhibitors in
8-day and 5-week growth assays (Figures S6D–S6F).
Since AKT is a convergent node downstream of many RTKs
and crucial to ERBB2+ cell growth, we compared BET bromo-
domain inhibitors to AKT inhibitors in combination with lapatinib.
In 8-day treatments of BT474 cells, the AKT inhibitor MK2206
alone or in combination with lapatinib induced multiple RTKs
(ERBB3, DDR1, IGF1R, FGFR2) and resulted in increased
FAK, SFK, and ERK phosphorylation (Figure 5H). Importantly,
JQ1 or I-BET151 alone was unable to completely suppress
signature kinase expression and signaling and only when com-
bined with lapatinib inhibited RTK expression and activity and
caused a loss of downstream FAK, SFK, AKT, ERK, and p70
S6K signaling (Figures 5H and S6G). This strongly suggests
JQ1 inhibits reactivation of oncogenic signaling by suppressing
the adaptive kinome response. 4-week growth assays indicated
that while AKT inhibitors (MK2206 and GSK690693) work well in
combination with lapatinib in BT474 cells, resistant colonies stillthe Presence and Absence of Lapatinib
itor) causes an increase in AKT phosphorylation in SKBR-3 but a decrease in
nedwith lapatinib causes a further inhibition of AKT phosphorylation after 24 hr.
growth. IGF1R/INSR inhibition has an additive effect with lapatinib inMDA361.
wth inhibition of other lines. SKBR-3 cells display synergism between lapatinib
varying degrees of growth inhibition by FAK or FGFR inhibition alone and in
ks, HCC1954 and MDA361 were treated for 5 weeks. Lapatinib doses: 100 nM
sented are mean ±SD of three technical replicates. *Significant difference from
lapatinib, 30 nM dasatinib, or a combination. Dasatinib inhibits MIB binding of
K phosphorylation but increases FAK phosphorylation.
n but increases AKT and ERK1/2 phosphorylation.
osphorylation at 4 hr but elicits strong reactivation by 48 hr. Combination with
lation. 300 nM lapatinib and 300 nM BGJ398 added directly to media at 0 hr.
fter 48 hr indicates FGFRs regulate multiple lapatinib-induced TKs.
b + kinase inhibitor in colony formation assays. Red, significant (p < 0.05); blue,
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Figure 4. Multiple Unrelated Kinases Contribute to the Growth of Lapatinib-Resistant Cells
(A) Parental or 300 nM lapatinib-resistant (LapR) SKBR-3 andBT474 cells were transfected with small interfering RNAs (siRNAs) against GAPDH (control) or ERBB
receptors and cultured for 96 hr. Both parental lines are strongly growth inhibited by ERBB2 and ERBB3 knockdown. LapR cells are less dependent on ERBB2 but
remain similarly dependent on ERBB3.
(B) MIB/MS long tail plots of most-activated kinases in LapR SKBR-3 and BT474 cells, relative to parental cells. Kinases in red are commonly over-activated in
SKBR-3 and BT474.
(C) MIB/MS profile of tyrosine kinases from LapR SKBR-3 and BT474 cells. LapR SKBR-3 cells display enhanced MIB binding of ERBB3, DDR1, FGFR2, MET,
FRK, and SRC. LapR BT474 have increased activity of multiple FGFRs, EPHA7, IGF1R, MERTK, MET, LYN, and FAK1. Data presented are mean of two biological
replicate MIB/MS experiments.
(D) Western blots indicate RTK upregulation in LapR SKBR-3 cells and reactivation of AKT/ERK signaling. LapR BT474 cells display suppressed activity of AKT
and ERK relative to parental cells. P, parental; R, LapR.
(E) 96-hr siRNA knockdown in LapR SKBR-3 cells indicates slight dependency on ERBB family and a stronger dependency on DDR1, FGFR2, and CDK5. BT474
cells are growth-inhibited by ERBB3, FGFR2, and CDK5 knockdown.
Data presented in (A) and (E) are mean ± SD of six technical replicates. Also see Figure S4.form in SKBR-3 and HCC1419 cells (Figure S6H). This contrasts
with the lack of colony formation in lapatinib + JQ1 combina-
tions across all lines. These findings further support disruption398 Cell Reports 11, 390–404, April 21, 2015 ª2015 The Authorsof AKT/ERK signaling networks leading to RTK upregulation
and a sustained blockade of the adaptive response by BET bro-
modomain inhibition.
Figure 5. BET Bromodomain Inhibition Suppresses Lapatinib-Induced Kinome Reprogramming and Arrests Growth
(A) Kinome reprogramming leads to transcriptional upregulation of multiple alternative kinases capable of reactivating or bypassing ERBB2-directed signaling.
We hypothesize by inhibiting the BET family of bromodomain-containing acetylation readers, we can prevent the adaptive response at an epigenetic level.
(B) Western blots demonstrate JQ1 (BET family bromodomain inhibitor) suppresses lapatinib-induced ERBB3 phosphorylation and expression at 300 nM and
inhibits reactivation of AKT in SKBR-3 cells. 48-hr treatments.
(C) Western blots indicate JQ1 blocks protein expression of multiple kinases involved in lapatinib resistance and leads to a decrease in ERBB family, SFK, FAK,
and PKCd phosphorylation. JQ1/lapatinib combinations inhibit AKT and p70 S6K phosphorylation more than lapatinib alone and increase cleavage of PARP.
48-hr treatments.
(D) qRT-PCR after 24-hr treatment shows JQ1 inhibits mRNA transcription of multiple RTKs involved in resistance (ERBB3,DDR1, FGFR2,MET) and suppresses
lapatinib-mediated induction.
(legend continued on next page)
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JQ1 Regulates Lapatinib-Induced Transcription and
Releases BRD4 and pSer2-Polymerase II from Adaptive
Kinase Genes
RNA-seq analysis demonstrated JQ1 downregulates 8% and
11% of genes at least 2-fold in SKBR-3 and BT474 cells, respec-
tively (Figures 6A and S7A). A smaller percentage was upregu-
lated 2-fold, with 3% in SKBR-3 and 5% in BT474, indicating
JQ1 affects transcription overall less than lapatinib. In combining
lapatinib and JQ1, we found that genes upregulated by lapatinib
were suppressed by JQ1 more than those unaffected or down-
regulated by lapatinib (Figures 6B–6E and S7B–S7E). Of tran-
scripts induced at least 2-fold by lapatinib in SKBR-3 cells,
adding JQ1 suppressed the induction of 27% by at least half,
and further upregulated just 4% (Figure 6C). Similarly, in BT474
cells JQ1 suppressed 28% of lapatinib-induced genes (Fig-
ure S7C). This indicates that JQ1 preferentially modulates lapa-
tinib-responsive gene expression. Reports indicate suppression
of MYC transcription is central to JQ1 function. BT474 cells
stably overexpressing c-Myc were less sensitive to JQ1, but
the combination of lapatinib + JQ1 still caused growth arrest
in SKBR-3 and cell regression in BT474 despite the rescue of
c-Myc levels (Figures S7F and S7G).
RNAi was used to inhibit the expression of BET family mem-
bers BRD2, -3, or -4 in SKBR-3 and BT474 cells (Figures 6F,
S7H, and S7I). BRD2 and BRD3 knockdown actually increased
target kinase transcription in response to lapatinib. In contrast,
lapatinib in combination with BRD4 knockdown was similar to
JQ1 in reducing lapatinib-mediated induction of ERBB3 and
DDR1 expression. Chromatin immunoprecipitation (ChIP)-PCR
demonstrated that JQ1 displaces BRD4 from the promoters
and upstream elements of lapatinib-induced kinase genes
ERBB2, ERBB3, FGFR2, and DDR1 (Figures 6G and S7J). KIT
is not expressed in SKBR-3 cells and serves as a negative con-
trol for ChIP-PCR analysis. JQ1 treatment also reduces the level
of the elongating form of RNA Polymerase II (phospho-Serine 2
of the C-terminal tail repeat; pS2-Pol2) binding to promoters
and internal exons of target kinase genes, consistent with tran-
scriptional inhibition (Figures 6G and S7J). Importantly, BRD4
and pS2-Pol2 are most effectively dissociated from chromatin
by combined lapatinib + JQ1 treatment, indicating synergism
between these drugs at an epigenetic level.
BET Bromodomain Inhibition Re-sensitizes Resistant
Cells to Lapatinib
RNA-seq of LapR SKBR-3 cells following 8-day treatment with
combinations of lapatinib with JQ1 or I-BET151 indicated tran-
scriptional suppression of a large proportion of TKs, including
those that contribute to growth (ERBB3, DDR1, FGFR2, and(E) 8-day growth curves demonstrate JQ1/lapatinib combination prevents growt
replicates.
(F) JQ1 in combination with lapatinib suppresses colony formation of SKBR-3 an
(G) BET family bromodomain inhibitors (JQ1, I-BET762, I-BET151) suppress colon
lapatinib in 4-week colony formation assays.
(H) Western blots indicate AKT inhibition (MK2206) induces RTK expression an
inhibition alone does not sustain inhibition of signature kinases, and only in comb
30 nM lapatinib, 100 nM MK2206, and 300 nM JQ1.
Data presented in (D), (F), and (G) are mean ± SD of three technical replicates. A
400 Cell Reports 11, 390–404, April 21, 2015 ª2015 The AuthorsMET; Figure 7A). Many outlier kinases from PCA (a representa-
tion of heterogeneity in the kinome response; Figure 2C) were
also suppressed by BET bromodomain inhibition (Figure 7B).
MIB/MS analysis from the same treatments indicated JQ1 and
I-BET151 inhibit or block the activity of the most-induced ki-
nases in LapR SKBR-3 cells relative to parental cells (Figure 7C).
Accordingly, JQ1 and I-BET151 inhibited the protein expression
and phosphorylation of signature kinases in LapR SKBR-3 and
BT474 cells, effectively reversing the adaptive kinome reprog-
ramming response (Figure 7D). Four-week clonogenic growth
assays demonstrated that the combination of lapatinib and
JQ1 arrested the growth of lapatinib-resistant cells (Figure 7E).
Furthermore, combinations of lapatinib and BET bromodomain
inhibitors were superior to combinations of lapatinib and kinase
inhibitors that only slowed the growth of LapR cells (Figure 7F).
Lapatinib + BET bromodomain inhibitor combinations were
even significantlymore effective than the triple combination of la-
patinib, dasatinib, and FAK inhibitor. This indicates that arresting
the transcriptional reprogramming response is more effective
than inhibiting the activity of multiple induced kinases. While
BET inhibitors arrested the growth of LapR cells in combination
with lapatinib, removal of lapatinib from the media while main-
taining JQ1 or I-BET762 in the culture allowed the cells to begin
growing again (Figure 7G). Thus, lapatinib and BET bromodo-
main inhibitor must be present in combination to effectively
inhibit growth; JQ1 or I-BET alone is not sufficient to inhibit
growth of the cells. Since LapR BT474 cells did not depend on
EGFR or ERBB2 for growth in the presence of lapatinib (Fig-
ure 4A), this indicates BET bromodomain inhibitors sensitize
cells to lapatinib by blocking alternative kinases involved in
adaptive growth responses.
DISCUSSION
In this study, we used MIB/MS to define lapatinib-induced
kinase activation dynamics on a kinome-wide level. This global
approach unveiled a robust network of kinases that compensate
for ERBB2 inhibition induced within 48 hr of lapatinib treatment,
indicating multiple potential mechanisms of resistance emerge
rapidly upon kinase inhibitor treatment. Inhibition of different
induced kinases in combination with lapatinib increased growth
inhibition across the five ERBB2+ cell lines to varying degrees.
Strong growth inhibition was observed by targeting FAK in com-
bination with lapatinib in SKBR-3 cells, indicating significant
synergism can be achieved if such vulnerable nodes are defined.
Heterogeneity in the adaptive kinome response, however,
makes identifying effective combination inhibitor treatments a
challenging task. Adding to the problem is the differentialh of SKBR-3 and BT474 cells. Data presented are mean ± SD of six technical
d BT474 cells after 4 weeks.
y formation of HCC1419 cellsmore so than kinase inhibitors in combinationwith
d ERK signaling alone and in combination with lapatinib. BET bromodomain
ination with lapatinib suppresses the adaptive response. 8-day treatment with
lso see Figures S5 and S6.
Figure 6. JQ1 Modulates Lapatinib-Induced
Transcription and Inhibits Epigenetic Regu-
lation of Signature Kinase Genes
(A) RNA-seq indicates JQ1 affects 11% of ex-
pressed genes 2-fold or more in SKBR-3 cells after
48-hr treatment.
(B) Figures 6C–6E refer to JQ1 effect on lapatinib-
regulated genes as indicated.
(C) JQ1 downregulates 27% of the 1,009 lapatinib-
induced genes by at least 2-fold from the lapatinib-
induced mRNA level.
(D) 1,000 genes not affected by lapatinib treatment
display a similar up- or downregulation profile in
the lapatinib+JQ1 combination compared to JQ1
alone.
(E) 964 genes at least 2-fold downregulated by la-
patinib are mostly unaffected by JQ1 as compared
to JQ1 alone or JQ1 effects on lapatinib-upregu-
lated genes.
(F) qRT-PCR demonstrates siRNA-mediated
knockdown of BRD2 and BRD3 enhances tran-
scription of ERBB2, ERBB3, FGFR2, and DDR1.
Knockdown of BRD4 suppresses ERBB3 and
DDR1 transcription, similar to JQ1. 24-hr siRNA
knockdown and then 24-hr drug treatment; 300 nM
JQ1, 300 nM lapatinib. Data presented are mean ±
SD of three technical replicates.
(G) ChIP-PCR indicates JQ1 inhibits BRD4 pro-
moter occupation in the absence of lapatinib. Loss
of BRD4 and elongating RNA Polymerase II (pS2-
Pol2) from upstream elements is maximal when
JQ1 is combined with lapatinib. 4-hr treatments
with 300 nM lapatinib and 300 nM JQ1 in SKBR-3
cells. Data presented are mean of three biological
replicate experiments.
Also see Figure S7.dependence of tumor cells on unrelated kinases in addition to
ERBB2. Together, these findings present a dilemma where com-
binations of any two or even three kinase inhibitors would be
insufficient to suppress the resiliency of the kinome and sustain
inhibition of tumor cell growth.
The five cell lines used in our study are each ERBB2+,
but HCC1954 and MDA361 are less sensitive to lapatinib
than the other three lines. MDA361 cells respond to inhibitors
of IGF1R/INSR, SFKs, FAK, and FGFRs in the absenceCell Reports 11, 390–of ERBB2 inhibition, suggesting intrinsic
resistance to ERBB2-targeted therapies
can be rooted in dependence on multiple
alternative kinases. Successful treatment
of such tumors would be difficult
with combinations of kinase inhibitors.
Heterogeneity of kinase expression in
different regions of the tumor would
further enhance this dilemma. Our study
demonstrates BET bromodomain inhibi-
tion provides an epigenetic mechanism
to target a series of kinases that mediate
resistance and sustain ERBB2+ cell
growth. Indeed, MDA361 cells are the
most sensitive to the JQ1/lapatinib com-bination treatment even though they are relatively insensitive
to lapatinib alone.
We acknowledge inhibition of major epigenetic regulators
such as BET bromodomain proteins has effects beyond the
blockade of adaptive kinome reprogramming. Histone deacety-
lase inhibitors such as panobinostat are in clinical use and have
been shown inmelanoma to suppress resistancemechanisms to
BRAF inhibition (Johannessen et al., 2013). We found panobino-
stat similarly blocks adaptive reprogramming in ERBB2+ breast404, April 21, 2015 ª2015 The Authors 401
Figure 7. BET Bromodomain Inhibition Suppresses Signature Kinases and Arrests Growth in Lapatinib-Resistant Cells
(A) RNA-seq after 8-day treatment of lapatinib-resistant (LapR) SKBR-3 cells with lapatinib + 300 nM JQ1 or 1 mM I-BET151 indicates transcriptional suppression
of the majority of tyrosine kinases.
(B) mRNA fold changes in outlier kinases identified by PCA (Figure 2C) indicates BET inhibitors suppress the majority of kinases that drive variation in the kinome
response.
(C) MIB/MS analysis of the top 20 most-activated kinases in LapR SKBR-3 cells following 8 days treatment with 300 nM JQ1 or 1 mM I-BET151 indicates the
majority of kinase activity is inhibited or blocked.
(D) Western blots of LapR SKBR-3 and BT474 cells treated with 300 nM JQ1 or 1 mM I-BET151 in combination with 300 nM lapatinib show suppression of
signature kinase expression and phosphorylation.
(E) 4-week colony formation assays demonstrate JQ1 suppresses colony formation and arrests growth of LapR SKBR-3 and BT474 cells in the presence of
lapatinib. Data presented are mean ± SD of three technical replicates.
(F) LapR BT474 cells are moderately growth-inhibited by combinations of lapatinib and other kinase inhibitors, but growth is completely suppressed by lapatinib
and bromodomain inhibitors (300 nM JQ1, 1 mM I-BET762, or 1 mM I-BET151), even more effectively than a triple kinase inhibitor combination (lapatinib +
dasatinib + PF228).
(G) Growth of LapR BT474 cells is arrested with 300 nM JQ1 or 1 mM I-BET762, but only in the presence of lapatinib.
Data presented in (F) and (G) are mean of six technical replicates ±SD.cancer cells, but it also displays significant cellular toxicity in the
absence of lapatinib. In contrast, we identified a significant
molecular synergism between BET bromodomain inhibitors402 Cell Reports 11, 390–404, April 21, 2015 ª2015 The Authorsand lapatinib that inhibited RNA polymerase II function, kinase
expression, and phosphorylation. The ChIP-PCR data with
SKBR-3 and long-term signaling studies with BT474 indicate
the combination of lapatinib and BET bromodomain inhibitors is
required to substantially suppress transcription of RTKs and pre-
vent reactivation of AKT/p70 S6K signaling. These effects are
not observed by JQ1 or I-BET151 treatment alone and suggest
BET bromodomain inhibitors target the epigenetic machinery
involved in the adaptive reprogramming response to lapatinib.
RNA-seq indicates approximately 2,000 expressed genes are
up or downregulated 2-fold or greater by lapatinib. This adaptive
transcriptome response involves a global reorganization of
signaling that is borne out by significant changes in kinome acti-
vation dynamics. This argues that targeting broad-acting epige-
netic regulators of transcription like BET bromodomain proteins
is not only advantageous, but needed to suppress this dramatic
induction of gene expression. JQ1 suppresses 27% of lapatinib-
induced transcripts by at least half, in contrast to 8% of genes as
a whole. JQ1 thus has a selective inhibition of lapatinib-induced
transcripts. Small interfering RNA (siRNA) experiments identified
BRD4 as participating in the reprogramming response. BRD4 is a
core component of the P-TEFb transcriptional elongation com-
plex (Jang et al., 2005; Yang et al., 2005) and regulates the phos-
phorylation of RNA polymerase II for activation of transcriptional
elongation of newly induced genes (Devaiah et al., 2012). Disrup-
tion of this complex by targeting BRD4 function provides an
elegant mechanism of how BET bromodomain inhibition might
regulate kinome reprogramming.
By targeting chromatin readers, we suppress expression of
the majority of kinases having a potential role in lapatinib resis-
tance and provide a method to address both the heterogeneity
in kinome response and inhibit a broad panel of kinases
known to drive ERBB2+ cancer cell growth. Recent studies
have described similar RTK networks comprised of ERBB recep-
tors,MET, IGF1R, and FGFRs that become upregulated after tar-
geted RTK inhibition (Singleton et al., 2013; Zhang et al., 2014). It
is conceivable that BET bromodomain inhibition would suppress
these kinases in other cancers as well and provide a means to
block the adaptive response to EGFR and FGFR inhibition
observed in these studies. We believe epigenetic enzyme-
targeting drugs will be key to preventing resistance rooted in
kinome reprogramming, thus making the action of kinase inhib-
itors durable. With at least four BET bromodomain inhibitors
in clinical trials, testing of a BET bromodomain inhibitor to
block adaptive responses induced with kinase inhibitors is a
possibility.
EXPERIMENTAL PROCEDURES
MIB Chromatography and LC/MS
MIB preparation and chromatography was performed as previously
described (Duncan et al., 2012). For multiplexing, peptides were labeled
with iTRAQ and separated on a 288 or 300 min 5%–45% ACN gradient as
a single fraction. ABSciex 5800 MALDI TOF/TOF and Thermo Q-Exactive
ESI mass spectrometers were used. For details, see Supplemental Experi-
mental Procedures.
For cell assays, statistics, western blotting, qRT-PCR, RNA-seq, and ChIP-
PCR, see Supplemental Experimental Procedures.
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